WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406209
CAS#: 146535-11-7
Description: AG1296 is a potent and specific inhibitor of the platelet-derived growth factor (PDGF) receptor tyrosine kinase.
MedKoo Cat#: 406209
Name: AG1296
CAS#: 146535-11-7
Chemical Formula: C16H14N2O2
Exact Mass: 266.10553
Molecular Weight: 266.29
Elemental Analysis: C, 72.16; H, 5.30; N, 10.52; O, 12.02
Synonym: AG1296; AG-1296; AG 1296; tyrphostin AG1296.
IUPAC/Chemical Name: 2-Phenyl-6,7-dimethoxyquinoxaline ; 6,7-Dimethoxy-2-phenylquinoxaline
InChi Key: QNOXYUNHIGOWNY-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H14N2O2/c1-19-15-8-12-13(9-16(15)20-2)18-14(10-17-12)11-6-4-3-5-7-11/h3-10H,1-2H3
SMILES Code: COC1=C(OC)C=C2N=CC(C3=CC=CC=C3)=NC2=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 266.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Watanabe T, Ohtani T, Aihara M, Ishiuchi S. Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models. J Neurosurg. 2013 Jan 11. [Epub ahead of print] PubMed PMID: 23311938.
2: Torres LA, Barbarroja N, Dorado G, Velasco F, López-Pedrera C. VEGF/KDR loop is a target of AG1296 in acute myeloid leukaemia showing FLT3-internal tandem duplications. Br J Haematol. 2009 Jun;145(6):836-8. doi: 10.1111/j.1365-2141.2009.07673.x. Epub 2009 Apr 8. PubMed PMID: 19388942.
3: Ueda S, Ikeda H, Mizuki M, Ishiko J, Matsumura I, Tanaka H, Shibayama H, Sugahara H, Takai E, Zhang X, Machii T, Kanakura Y. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296. Int J Hematol. 2002 Dec;76(5):427-35. PubMed PMID: 12512837.
4: Kovalenko M, Rönnstrand L, Heldin CH, Loubtchenkov M, Gazit A, Levitzki A, Böhmer FD. Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry. 1997 May 27;36(21):6260-9. PubMed PMID: 9174341.
